The FDA has approved a new formulation of the blood thinner Argatroban, called Argatroban in Sodium Chloride injection, for adults with a rare condition called heparin-induced thrombocytopenia (HIT). HIT is a serious reaction to the common blood thinner heparin that can cause dangerous blood clots. This new drug helps prevent or treat those clots. It is also approved for use during a procedure to open blocked heart arteries (percutaneous coronary intervention) in patients who have or are at risk for HIT.
This version of Argatroban comes as a ready-to-use liquid in a glass vial. It is given through a vein (intravenous infusion) and does not need to be mixed or diluted before use. This can save time and reduce the chance of errors for healthcare providers. The drug works by directly blocking thrombin, a key protein in blood clotting.
The approval is based on studies showing that Argatroban is effective and safe for these uses. However, like all blood thinners, it increases the risk of bleeding. The dose must be carefully adjusted based on blood tests to make sure it is working properly and safely.
If you or a loved one has HIT or is at risk for it, talk to your doctor about whether this treatment is right for you. This approval does not mean it is appropriate for everyone with clotting problems. Your doctor can help weigh the benefits and risks based on your personal health history.